Professional Documents
Culture Documents
SOLOMON HABTEMARIAM
Pharmacognosy Research Laboratories & Herbal Analysis Services UK, University of Greenwich,
London, United Kingdom
Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
© 2019 Elsevier Ltd. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical,
including photocopying, recording, or any information storage and retrieval system, without permission in writing from the
publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our
arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at
our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be
noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding,
changes in research methods, professional practices, or medical treatment may become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information,
methods, compounds, or experiments described herein. In using such information or methods they should be mindful of
their own safety and the safety of others, including parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any
injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or
operation of any methods, products, instructions, or ideas contained in the material herein.
xiii
Preface
Plants provide by far the most essential intervention from disease prevention to
nutrients of the human diet such as carbohy- management as well as public education is
drates, fats, proteins, vitamins and minerals. necessary. Measures of T2D management in-
Collectively called plant foods, they are con- clude life style changes such as dietary inter-
sumed to generate energy and maintain our vention, exercise, and weight loss where
normal body physiology or homeostasis. Be- necessary, and drug interventions. At the
yond these vital nutrients, plants do also syn- forefront of dietary intervention measures
thesize a variety of compounds that are are the balancing act of calorie intake and ex-
called ‘secondary metabolites’ with func- penditure and promoting what are consid-
tions often associated with defense against ered as good diets or healthy foods.
pathogens, herbivores or for allelochemical Perhaps the most important therapeutic
interactions. The exploitation of these valu- breakthrough in diabetes pharmacotherapy
able chemical compounds by mankind have is associated with the discovery of insulin
been evident from prehistoric period of and its application that is dated back to the
herbal medicines utilization to the significant 1920s. Since then, numerous classes of com-
proportion of today’s modern medicine pounds of biological/protein/peptide and
which trace their origin back to natural prod- small molecular weight compounds both
ucts. The use of plants for flavoring and from synthetic and natural product sources
spices as well as exploitation for dyes, cos- (or natural products-inspired synthesis) have
metics, agrochemical and other industries been introduced. The requirement of long-
also serve as good examples of plant second- term or life-time treatment coupled with the
ary metabolites applications for human use. numerous side-effects of these drugs still push
While advance in drug discovery and de- us, however, to desperately search for new
velopment in the last two centuries have therapies of T2D. In addition to insulin, the
made it possible to control/manage various incretin analogues such as glucagon-like pep-
diseases, or to improve the quality of life, tide mimics or exendin-4 from the saliva of the
there have also been continued challenges venomous Gila monster, which served as a
from emerging or the modern-era diseases synthesis framework for novel antidiabetic
that are not yet met by effective drug thera- agents, underpins nature as a source of
pies. The classical example is the complex protein/peptide-based antidiabetic drugs.
metabolic disease of type 2 diabetes (T2D). On the small-molecular weight side, our first
The epidemic proportion of recent increase line pharmacotherapy for T2D is still with
in the incidence of this disease along with metformin which is the biguanides class of
its major risk factor, obesity, brought signifi- compounds discovered form research based
cant burdens to our societies, governments on the medicinal application of the plant
and healthcare services. In the absence of Galega officinalis as antidiabetic agent. The ra-
drug of cure, a coordinated system of tional for identifying novel drugs of natural-
xv
xvi PREFACE
origin for T2D is thus as good as it has ever extensively presented. In addition to the nor-
been and plants that have already been used mal physiological regulations of carbohy-
by mankind for centuries and considered safe drate/lipid metabolism from digestion in
have even more added value if they are the gut to absorption, storage and utilization;
proven to be efficacious. pathological dysregulations and the major
At the junction between what constitute molecular/biochemical targets for drug ther-
food and medicine are the medicinal foods. apy are outlined. One chapter is also dedi-
These include plant food ingredients which cated in this section for pathological
are known to contain a range of secondary features of diabetes complication at macro-
metabolites that act through-drug like effects and microvascular and/or cellular levels.
when they are consumed in sufficient In Section-C, an overview of the current
amount. The various flavoring and spice therapeutic agents for T2D along with their
plants such as ginger, garlic, turmeric, clove, mechanism of action are illustrated. The bio-
fenugreek, etc. may be included into this cat- synthesis machinery of plants secondary
egory. While some plant foods are regularly metabolites and what classes of compounds
consumed in some regions, they may be rare are expected from natural sources are also
or considered medicinal in other regions of discussed in this section. As such, the princi-
the world. For example, we have plants like ples of drug action applicable to potential
Moringa which are eaten as staple food therapy of T2D by plant secondary metabo-
in East Africa and India while they are lites are outlined.
primarily used as herbal medicines in other The choices of plants as medicinal foods
parts of the world. While fruits like figs was based on extensive review of the scien-
and olives are consumed as food, other plant tific literature and the profile of plant-based
parts of these plants such as their leaves are products in the market relevant to the food,
either routinely employed in herbal medi- nutraceutical and plant-based therapies. On
cine applications or as herbal teas and infu- these basis, three sections (Sections D–F)
sions with some therapeutic implications. are dedicated to exhaustively appraise the
The vast arrays of herbal medicines are also chemistry and pharmacology of the chosen
recently repurposed as food supplements plants. With over 2270 chemical entries
and are widely available in health shops as backed up with 4258 citations, this book is
over-the-counter medicinal/nutraceutical intended to provide readers with the most
products. Hence, the distinction between comprehensive and up-to-date information
what we consider as food and medicine is on the chemical and biological domains of
even now becoming more and more blurred. these medicinal plants and/or foods. On
This book is intended to provide a com- the pharmacological side, all available re-
prehensive resource on T2D and associated sources from in vitro, the plethora of animal
diseases from pathology to intervention by studies and human trials are systematically
natural products that come under plant scrutinized. Mechanistic approach from in-
foods of medicinal importance. Section-A sulin signaling and insulin resistance to gen-
provides basic facts on T2D from significance eral mechanisms of actions such as
as a global burden and prevalence (along antioxidant and anti-inflammatory effects
with obesity) to its definitions, classifications are extensively discussed. These include
and diagnostic criteria. In Section-B, the data from the chemical-, diet- and
basic carbohydrate and lipid metabolism as genetically-induced cellular and animal
well as pathological hallmarks of T2D are models of obesity and/or T2D. Along with
PREFACE xvii
obesity, the T2D associated diseases such as this section, one chapter is dedicated to in-
hypertension, diabetes retinopathy, neurop- clude medicinal foods that are emerging to
athy, nephropathy and wound complica- gain interest both scientifically and in the
tions are all used to show pharmacological public domain as T2D modulating agents
and clinical efficacies for the crude medicinal and include, cocoa (Theobroma cacao), coco-
plant/food preparations as well as their ac- nut (Cocos nucifera), figs (Ficus carica),
tive principles. Under each chapter, the his- Moringa (Moringa oleifera and M. stenopetala),
torical perspectives of the plants as food soybean (Glycine max), sweet potato (Ipomoea
and medicine, their botanical description batatas), and walnuts (Juglans regia). The last
and taxonomic significance are presented chapter is dedicated to the large volume of
along with the relevant chemistry and phar- information on herbal medicines that are
macology. Beyond the detailed pharmaco- now repurposed as food supplements. The
logical effects at in vitro, in vivo and merits of these products as dietary supple-
clinical conditions, their pharmacokinetic ments with intention to modulate T2D
and toxicological profiles are also discussed. and/or metabolic syndrome are scrutinized
Section-D exhibits fruits that have been with the following key examples: Aloe vera
shown to modulate T2D and the various (L.) Burm. F., Andrographis paniculata (Burm.
components of metabolic syndrome. This in- F.), Wall. Ex Nees, banaba (Lagerstroemia
clude chapters on bilberries and blueberries, speciose (L.) Pers), Cassia or Senna species (in-
bitter melon (Momordica charantia L.), guava cluding Senna auriculata (L.) Roxband S. alata
(Psidium guajava L.), okra (Abelmoschus (L.) Roxb.), Ginkgo biloba L., ginseng (Panax.
esculentus (L.) Moench), papaya (Carica pa- ginseng C.A. Mey, P. quinquefolius L. and P.
paya L.), pomegranate (Punica grantum L.), notoginseng), gymnema (Gymnema sylvestre
prickly pear cactus (Opuntia species) and the (Retz.) R.Br. ex Sm.), Jamun (Syzygium cumini
various pumpkins (Cucurbita species). In ad- (L.) Skeels), olive leaf extract (Olea europaea
dition to the fruits of these plants, discus- (L.)), scutellaria (Scutellaria baicalesis Georgi)
sions on other plant parts as emerging and St John’s wort (Hypericum perforatum L.).
potential therapeutic agents are also in- Finally, this book is not intended to advo-
cluded. Section-E is devoted to the flavour cate the medicinal foods cited herein to serve
and spices groups that have shown to have as a replacement therapy to insulin, metfor-
significant health benefits in recent years min or other antidiabetic pharmacotherapy
and include chapters on cinnamon in use today. It is a rather balanced appraisal
(Cinnamomum species), cloves (Syzygium of all the available data at hand with all neg-
aromaticum (L.) Merr. & L.M. Perry), fenu- ative and positive outcomes of pharmacolog-
greek (Trigonella foenum-graecum L.), ginger ical and clinical efficacies presented with the
(Zingiber officinale Roscoe), garlic (Allium source of data variabilities, where appropri-
sativum L.), and turmeric (Curcuma longa ate, identified and scrutinized. In fact, the au-
L.). Of the beverages included in Section-F thor, acknowledges that pharmacological
are those known to modulate the diabetes data discrepancies for plant preparations, es-
pathology, but most importantly in reducing pecially under clinical trial studies, reflects
the diabetes prevalence/risk based on epide- the challenges and frustrations of using me-
miological and clinical data, are coffee, tea dicinal foods or their products as medicine.
(Camellia sinensis (L.) Kuntze), rooibos Hence, the sources of controversies in effi-
(Aspalathus linearis (Burm. F.), and yerba cacy and chemical composition variability
mate (Ilex paraguariensis A. St.-Hil.). In the for medicinal foods based on genetic and
xviii PREFACE
environmental factors that govern plant sec- researches, professionals in healthcare ser-
ondary metabolites; harvesting, processing, vices, and those with interest in the herbal,
and manufacturing conditions; experimental food and pharmaceutical industries. Stu-
models and designs including dosage, inter- dents and scientists in medical, pharmaceuti-
vention time and assessment criteria, etc. are cal and food science disciplines are other
all taken into consideration. The author be- beneficiaries of the book.
lieves that the book would be an invaluable
resource to scientist in drug discovery Solomon Habtemariam
Acknowledgements
I would like to thank a number of people Kerala (India) has also been generous in in-
who kindly gave me images of some plants troducing me to the medicinal foods of rele-
used in this book, particularly Dr Helen Pick- vance in Asia. Images of a number of food
ering of the Kew Botanical Garden, UK; ingredients and medicinal/nutraceutical
Dr Jianhua Xie (State Key Laboratory of products have been taken from health shops
Food Science and Technology, Nanchang particularly Holland and Barret with the
University, Nanchang, China); and Professor kind assistance of staff to whom I am grate-
Susana Casal (REQUIMTE/Laboratory ful. I did extensively use the Kew Botanical
of Bromatology and Hydrology, Faculty of Garden (London, UK) resources and this
Pharmacy, Porto University, Rua Jorge included acquiring images of the numerous
Viterbo Ferreira, Porto, Portugal). Dr George medicinal plants in the garden and their
Varghese of Kerala, my very good friend, excellent library services as well as online
who also supported me during my trip to databases.
xix
C H A P T E R
1
Type-2 diabetes: Definition,
diagnosis and significance
O U T L I N E
1.1 Diabetes
Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases 3 # 2019 Elsevier Ltd. All rights reserved.
https://doi.org/10.1016/B978-0-08-102922-0.00001-8
4 1. Type-2 diabetes: Definition, diagnosis and significance
The underlying causes of diabetes are either insufficient insulin production due to pancre-
atic β-cell destruction, insulin resistance, or a combination of both. For this, several pathogenic
processes are involved leading to the development of abnormalities in carbohydrate, fat, and
protein metabolism. Historically, DM was classified as either Insulin Dependent Diabetes
Mellitus (IDDM) or Non-Insulin Dependent Diabetes Mellitus (NIDDM). The classification
of DM is now, however, mainly based on the disease aetiology as follow:
Type 1 diabetes (T1D): This includes either immune-mediated or idiopathic forms of β-cell
destruction, which leads to absolute insulin deficiency. Insulin resistance is not common
herein and therefore total dependency upon externally administered insulin is required
for maintaining life.
Type 2 diabetes (T2D): This involves a progressive loss of β-cell insulin secretion often
coupled with insulin resistance. The disease has usually an adult onset that may begin with
the body being insensitive to insulin and some form of insulin deficiency. The aetiology of
T2D has a very strong component of genetic predisposition.
Type 3 diabetes: This category includes a wide range of specific types of diabetes resulting from
some form of genetic defects in insulin action or diseases. Examples include the monogenic
diabetes syndromes such as the neonatal diabetes and maturity-onset diabetes of the young
(MODY), diseases of the exocrine pancreas with cystic fibrosis as a well-established cause,
and drug/chemical-induced diabetes including the prolonged usage of glucocorticoid fol-
lowing organ transplantation, management of AIDS, etc.
Type 4 diabetes: Gestational diabetes mellitus (GDM) often diagnosed during the second or
third trimester of pregnancy.
Historical perspectives into the classification of diabetes starting from the two forms of in-
sulin sensitive and insulin-insensitive types described by Himsworth in 1936 to the various
aetiology-based definition of today are presented by Wild and Byrne (2013). With the
aetiology of DM and its major risk factors including obesity are well established in recent
years, the standardised classification and diagnostic criteria have been published by the
World Health Organization (WHO). Such documents (e.g. that published in 1980) were also
subjected to regular revisions. For example, the 1985 update described DM classification as
IDDM and NIDDM, malnutrition-related diabetes mellitus (MRDM), gestational diabetes,
and other types of diabetes. The 1999 WHO revision, on the other hand, replaces the IDDM
and NIDDM, which reflect treatment rather than aetiology, by T1D and T2D, respectively.
Under the present aetiology-based classification, the primary cause of T1D is pancreatic
islet β-cell destruction where patients are prone to ketoacidosis. This includes the
autoimmune-mediated destruction of β-cells and other forms called the idiopathic T1D where
neither the pathogenesis nor the causes are known. When the specific cause of the β-cell de-
struction is identified, as in the cases of cystic fibrosis, mitochondrial defects, etc., they are not
classified as T1D. In order to avoid ketoacidosis, coma and death, T1D patients need insulin
administration. One common feature of T1D is the detection of antibodies as markers of the
autoimmune β-cell destruction processes including anti-GAD (glutamic acid decarboxylase
autoantibodies) or insulin antibodies. In the idiopathic T2D cases that is commonly expressed
in non-Caucasians, however, markers of the autoimmune process may not be evident.
through random screening, high risk group during routine check-up, and most commonly in
patients presenting the classical symptoms. As discussed in the various chapters of this book,
the same diagnostic criteria are used to monitor glycaemic control and efficacy of drugs in
both experimental animals and human clinical studies.
Recent approaches on diabetes intervention also gave considerable emphasis on managing
prediabetic cases where an increased level of FBG is evident but is still below the threshold
level of diabetes. This prediabetes state is often in the region of FBG of 100–125 mg/dL
(5.6–6.9 mmol/L) and is also called impaired fasting glycaemia (IFG) or impaired glucose
tolerance (IGT). Another marker of prediabetes is impaired glucose tolerance (IGT) of 140
and 199 mg/dL (7.9–11.0 mmol/L) plasma glucose in the 2-h OGTT or an HbA1c level of
5.7–6.4%. Some estimates suggest that unless a drastic measure is taken in the form of lifestyle
changes and therapeutic interventions, about 70% of prediabetics could develop a full-blown
diabetes in less than 10 years (Tabák et al., 2012). In this context, the HbA1c level of >6% may be
considered as high risk threshold for developing diabetes and is qualified for starting a ther-
apeutic measure. The major risk factor of diabetes being obesity and age, screening for diabetes
is also recommended for older and/or overweight people. Other risk factors for prediabetes/
diabetes are of course lack of physical activity, ethnicity/genetics, and clinical conditions such
as cardiovascular diseases. Classification of diabetes, diagnosis, and treatment guidelines
provided by the American Diabetes Association is a good reference material (ADA, 2018).
The common diabetes symptoms that are often taken as indicators for initiating diagnosis
are worth mentioning. These are related to the pathological changes and metabolic dysfunc-
tion associated with the disease and may give some clue about the class of diabetes as shown
in Table 1.1.
The World Health Organisation (WHO) regularly publishes facts and figures for DM, and
its 2016 global estimates (WHO, 2016) indicated 422 million adults aged over 18 years living
with diabetes in 2014. The comparative assessment of diabetic cases over the years also indi-
cated that the figure in 1980 was 108 million suggesting a drastic increase in diabetic cases.
This corresponds to the global prevalence of diabetes growing from 4.7% in 1980 to 8.5% in
2014, during which time prevalence has increased or at the very best remained unchanged.
For such assessment, the WHO divides the world countries into six zones/regions as shown
in Fig. 1.1. The prevalence of diabetes for the different regions of the world by percentage and
actual population size is also shown in Fig. 1.2. The highest rate of increase in T2D now
appeared to be in the East Mediterranean region (EMR), while the largest number of diabetes
sufferers are located in the Western pacific region followed by South-East Asia region
(Fig. 1.3).
Another significance of diabetes prevalence in recent years is the changing age boundary
for the disease. From being a disease of the middle-aged and elderly people, T2D is now fre-
quently seen in children and young people. The proportion of undiagnosed T2D has also been
widely estimated to be between 24% and 62%. Another, and a rather disturbing figure by the
WHO (2016), is on the prevalence of the major risk factor of DM, obesity, which is presented as
follow:
FIG. 1.1 The WHO classification of the world regions for assessment of disease prevalence.
10 500
1980 1980
Global Diabetes
Prevalence (%)
(Millions)
6 300
4 200
2 100
0 0
80 14 80 14
19 20 19 20
(A) Year (B) Year
FIG. 1.2 Global prevalence of diabetes in percentage of population (A) and number (B). Source: WHO, 2016. Global
report on diabetes http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf (Accessed 31.12.18).
Key fact:
• Worldwide obesity has more than doubled since 1980.
• In 2014, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 600 million
were obese.
• 39% of adults aged 18 years and over were overweight in 2014, and 13% were obese.
• Most of the world’s population live in countries where overweight and obesity kills more people
than underweight.
• 41 million children under the age of 5 were overweight or obese in 2014.
• The worldwide prevalence of obesity more than doubled between 1980 and 2014.
Hence, the diabetes epidemics appear to be going hand in hand with obesity. Moreover,
the WHO figure in 2014 showing an estimated 41 million children under the age of 5 years
in the world as overweight or obese is indeed alarming. In less economically developed coun-
tries such as Africa, the number of overweight or obese children also nearly doubled from 5.4
million in 1990 to 10.6 million in 2014 while nearly half of the children under 5 in Asia were
classified as overweight or obese during the same time period.
As discussed in Chapter 4, diabetes is a leading cause of damage to the heart, blood vessels,
eyes, kidneys, and nerves, among others. Inevitably, diabetes increases the risk of heart at-
tacks and strokes. The endothelial dysfunction and reduced blood flow, together with neu-
ropathy, increase the chance of foot ulcers which is susceptible to infection and eventually
leads to limb amputation. Diabetes retinopathy due to extensive capillary formation or angio-
genesis is a leading cause of blindness associated with the disease. Diabetes also remains to be
the main cause of kidney failure making the disease as a priority area both for reducing the
quality of life and cause of death.
The direct medical costs and loss of work associated with diabetes is enormous and the
disease along with obesity is considered a condition that might bankrupt the health care sys-
tem of many countries in the very near future. The WHO indicates that in 2012, there were 1.5
million deaths worldwide directly caused by diabetes. The total burden of deaths from high
blood glucose was even estimated to be higher and in 2012, it was 3.7 million, i.e., an addi-
tional 2.2 million deaths could be attributed to diabetes-associated diseases such as cardiovas-
cular diseases, chronic kidney disease, and tuberculosis related to higher-than-optimal blood
glucose. The WHO (2016) data further estimates that the largest number of deaths resulting
from high blood glucose occurs in upper-middle income countries (1.5 million) and the lowest
number in low-income countries (0.3 million).
According to Diabetes UK (2018), the cost of diabetes to the National Health Service (NHS)
was as follow:
• Over £1.5 million an hour or 10% of the NHS budget for England and Wales, i.e., over
£25,000 every minute
• About £14 billion pounds a year for treating diabetes and its complications
• The cost of treating diabetes complications is higher than the cost of treating diabetes
(blood glucose control) itself
Data for the cost of diabetes in the United States have also been estimated by various gov-
ernment departments and organisations. The American Diabetes Association (2018) put the
estimated cost of diagnosed diabetes in 2012 as $245 billion of which $176 billion was direct
medical costs and $69 billion for the reduced productivity due to the diabetes burden. A 41%
increase of the cost over a 5-year period was also reported. One could thus imagine the global
cost of diabetes and associated diseases now and for the next few years.
References
ADA (American Diabetes Association), 2018. The cost of diabetes. http://www.diabetes.org/advocacy/news-
events/cost-of-diabetes.html. (Accessed 31 December 2018).
Diabetes UK, 2018. Cost of diabetes. Available at: https://www.diabetes.co.uk/cost-of-diabetes.html (Accessed
31 December 2018).
Tabák, A.G., Herder, C., Rathmann, W., Brunner, E.J., Kivim€aki, M., 2012. Prediabetes: a high-risk state for diabetes
development. Lancet 379 (9833), 2279–2290.
WHO, 2016. Global report on diabetes. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.
pdf. (Accessed 31.12.18).
Wild, S.H., Byrne, C.G., 2013. Commentary: sub-types of diabetes—what’s new and what’s not. Int. J. Epidemiol.
42, 1600–1602.
Further reading
American Diabetes Association Standards of Medical Care in Diabetes, 2017. Classification and diagnosis of diabetes.
Diabetes Care 40 (Suppl. 1), S11–S24.
2
Glucose metabolism: Normal
physiology, diabetic dysregulation, and
therapeutic targets
O U T L I N E
2.1 Introduction
The level of glucose in the blood is tightly regulated within a narrow window of concentra-
tion range through intricate balance of glucose generation and removal mechanisms. The pri-
mary source of glucose pool in the blood is derived from dietary carbohydrates from the gut,
the release of glucose from storage, primarily in the liver through glycogenolysis, and synthesis
of glucose (gluconeogenesis) in the body from other sources such as amino acids, lactic acids,
and other reaction intermediates. Glucose is taken up from the blood virtually by all cells in the
body for energy generation. Upon the complete oxidation of glucose through aerobic mecha-
nism, 36 molecules of ATP are generated per molecule of glucose, while incomplete oxidation
Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases 13 # 2019 Elsevier Ltd. All rights reserved.
https://doi.org/10.1016/B978-0-08-102922-0.00002-X
14 2. Glucose metabolism
through anaerobic or glycolytic route can generate two molecules of ATP per glucose molecule.
Beyond energy generation, the metabolism of glucose in the energy generation process involv-
ing glycolysis and the ‘Krebs Cycle’, also known as the ‘Citric Acid Cycle’ or the ‘Tricarboxylic
Acid Cycle (TCA)’ offer numerous essential ingredients for the synthesis of fatty acids, steroids,
cholesterol, amino acids, the purines and pyrimidines and various other biological molecules.
As excess amount of glucose is always excreted through the kidney, conservation of this vital
metabolic source during postprandial excess in the blood is carried out in the liver and muscles
by storing it in the form of glycogen. In the following sections, the major processes of glucose
metabolism along with the key regulatory mechanisms and potential target areas for therapeu-
tic interventions in type 2 diabetes (T2D) are discussed.
Large food particles are broken down into small pieces through mechanical (e.g. chewing in
the mouth and the churning and grinding of food by the stomach) and chemical processes.
While the mineral components of food along with others such as vitamins (micronutrients)
are released from smaller food particles, major food nutrients such as carbohydrates, fats,
and proteins are subjected to a number of enzymatic chemical processing throughout the gas-
trointestinal (GIT) system. The main carbohydrate sources of the human diet are complex poly-
saccharides such as starch, the disaccharide sucrose (our common sweet choice, table sugar),
the lactose of milk origin, and the maltose mainly from the grain source (e.g. brewed products).
The major carbohydrates of the human food from sources such as potatoes, wheat, corn,
and rice are stored in the form of starch which is composed of the linear and helical amylose
units and branched amylopectin. As explained in the later sections, the chemical composition
of the polysaccharides with respect to the bonds between the sugar units are important fea-
tures governing their digestibility. The water insoluble helical polymer of amylose is made of
α-D-glucose monomers joined through α(1 ! 4) glyosidic bonds (Fig. 2.1). On the other hand,
the water soluble amylopectin has the linear α(1 ! 4) glycosidic bonds that exhibit a repeat-
ing (every 24–30 glucose units) branching via α(1 ! 6) bonds (Fig. 2.1).
For utilization by the body as an energy source, only the monomers of disaccharides and
polysaccharides are taken up by the blood and hence complete breakdown of carbohydrates
to their monomeric building blocks must be achieved in the gut:
Starch ! glucose
Sucrose ! glucose + fructose
Lactose ! glucose + galactose
Maltose ! glucose
Enzymatic digestion of carbohydrate start in the mouth where the amylase with an opti-
mum pH of 7 acts on starch to give di- and trisaccharides as well as smaller branched dextrin
fragments. The enzyme acts on the α(1 ! 4) glycosidic bonds in the starch or amylose sugars.
It does also cleave these bonds in the amylopectin although the branching points that contain
α(1 ! 6) glycosidic bonds are unaffected. Until the enzyme is neutralized by the acidic envi-
ronment in the stomach that denature it, salivary amlylase breaks down starch into smaller
components in readiness to be acted by other enzymes.
FIG. 2.1 Structures of amylose and amylopectin. The numbering of carbons of glucose molecules is also shown.
FIG. 2.2 The location of α-glucosidease in the intestine. The intestinal cells, enterocytes, have microvilli structural
feature in the luminal or apical-end called brush border that contain a variety of carbohydrate digestive enzymes.
These enzymes collectively called the α-glucosidases include maltase, sucrose, lactase, and α-dextrinase. The
resulting glucose and other nutrients and minerals released from the food are absorbed to the cells to be transferred
to the blood via the interstitial fluid at the junction between enterocytes and the blood vessels.
The major enzymatic digestion of carbohydrates occurs in the small intestine. As with the
salivary amylase, pancreatic amylase with the optimum pH of 7 acts on polysaccharides to
release small branches (dextrins—oligosaccharides containing at least one α (1 ! 6) glyco-
sidic bond/branch), disaccharides (e.g. sucrose, maltose, and lactose), trisaccharides
(matotriose), and glucose. The larger units (di-, tri-, and polysaccharides) are finally
processed by the membrane-bound intestinal brush border enzymes (Fig. 2.2) as follow:
• Glucoamylase hydrolyses maltose and maltotriose
• Dextrinase hydrolyses dextrin by acting on the α(1 ! 6) glycosidic bonds
• Sucrase hydrolyses sucrose to generate glucose and fructose
• Lactase hydrolyses lactose to generate glucose and galactose
• Maltase converts maltose to glucose
The resulting monomeric carbohydrates such as glucose, fructose, and galactose released
by ectoenzymes of the brush border cells are then absorbed by the enterocytes (see Section 2.3
below for uptake mechanisms). Given that the α(1 ! 4) bond in carbohydrates of the human
diet is the major significance, enzymes acting on this bond, collectively called α-glucosidases,
are playing key role in making glucose available for uptake into the blood stream. Hence, in-
hibition of these enzymes constitutes a major mechanism of antidiabetic effect by pharmaceu-
tical agents whereby the level of glucose in the blood is suppressed through inhibition of
carbohydrate digestion.
A number of complex carbohydrates including cellulose are not digested in the human
body due to lack of the necessary enzymes. These indigestible polysaccharides are collectively
called dietary fibres that may be soluble or insoluble and contribute to food/stool mobility
within the digestive system (e.g. the colon).
Key facts:
The major step in the digestion of carbohydrate and release of glucose into the blood stream involve
the group of enzymes in the intestine collectively called α-glucosidases. Inhibition of these enzymes
that cleaves the α(1 ! 4) bonds is one mechanism of antidiabetic effects by pharmaceutical agents
and natural products such as medicinal foods. Indigestible carbohydrates or polysaccharides are
dietary fibres that modify the normal function of the gut and also have applications in antidiabetic
therapy.
Once carbohydrates are completely digested to release their monomers such as glucose,
galactose, and fructose, they are absorbed by the intestinal brush-border cells via different
transporters. The predominant means of glucose absorption across the cell membrane of these
cells is through the Na+-dependent glucose transporter protein-1 (SGLT1). There is also an-
other transporter, SGLT2 but its major role as glucose transporter is in the kidney for glucose
reabsorption following glomerular filtration. These membrane proteins couple the transport
of two molecules of Na+ ions with one molecule of glucose (Fig. 2.3). A number of studies (e.g.
Kipnes, 2011; Musso et al., 2012) have established these two glucose transporters as follow:
• The SGLT2 is a high-capacity and low-affinity protein, whereas SGLT1 which is low-
capacity and high-affinity protein transporter;
• SGLT2 is predominantly expressed at the proximal renal tubules and accounts for
reabsorption of up to 90% of glucose;
• SGLT1 is predominantly expressed at the apical side of the intestinal brush border cells and
late proximal renal tubules;
• SGLT1 also transports galactose;
• Both SGLT1 and SGLT2 can be targeted by antidiabetic agents to suppress the raised
plasma glucose level in T2D.
FIG. 2.3 Glucose absorption at the apical membrane of the enterocytes. The SGLT1 couples the transport of one
molecule of glucose while co-transporting two molecules of Na+.
FIG. 2.4 Glucose exit from enterocytes via the basolateral membrane. The GLUT2 is primarily used to transport
glucose down its concentration gradient without a need for ATP. The facilitated transport system through conforma-
tional changes of the protein is shown from A to D.
Once enterocytes are loaded with glucose, they release it to extracellular medium near the
blood capillaries via the basolateral membrane through glucose transporter protein-2
(GLUT2). The transport of glucose by GLUT2 is a facilitated-diffusion as depicted in Fig. 2.4.
GLUT2 has also shown to be involved in the entry of glucose into enterocytes through the apical
cell membrane. The protein is translocated from the cytoplasmic vesicles into the apical mem-
brane to enhance glucose transport. Readers should also bear in mind that the excess sodium ions
gained in the enterocytes by the SGLT1 action could be cleared via the Na+/K+ energy dependent
pump at the basolateral membrane.
To date, several glucose transport proteins in the various tissues have been identified. All
of them are mediating a passive facilitated diffusion system across cell membranes without
requiring metabolic energy. The GLUT1 and GLUT3 are high affinity glucose transporters
and play major role in the brain although they are also present in many cell types. They trans-
port glucose efficiently throughout the normal range of plasma glucose concentration. The
GLUT2 is a low affinity glucose transporter mainly located in the pancreas and liver. Unlike
the high affinity GLUT1 and GLUT3, GLUT2 function during high plasma glucose levels as
well as glucose absorption in the enterocytes following glucose excess after meal. Hence,
GLUT2 can serve as a glucose sensor by which pancreatic β-cells and liver cells respond to
high glucose concentration to respond by hormonal secretion (e.g. insulin) and glycogenesis,
respectively.
The GLUT4 is the major glucose transporter in muscles and adipose tissues and its function
is highly regulated by hormones such as insulin. The protein is normally stored in intracel-
lular vesicles and is translocated to the plasma membrane upon cellular stimulation by insu-
lin. On the other hand, the glucocorticoids such as cortisol suppress the level of GLUT4 on
plasma membrane. The GLUT5 is known to function in the ilium and the liver and known
to be primarily transporting fructose. Obviously, more GLUT proteins will be characterized
in the future and GLUT6 and GLUT7 are beginning to be understood; in the latter case as
glucose-6-phosphate (G6P) transporter into the endoplasmic reticulum within the liver.
The roles of GLUT4 in muscles and adipocytes, its functional regulation, and as a therapeutic
target in diabetes are extensively discussed in the various sections of this book.
Key fact:
Once glucose is released in the small intestine through the action of carbohydrate digesting en-
zymes, it is taken up to the blood steam via the enterocytes. The entry of glucose to this cells, pri-
marily by SGLT1, and exit via GLUT2 can be targeted by drugs or natural products. Undigested
carbohydrates or dietary fibres that physically hinder the absorption of glucose could also lower
glucose availability to the blood.
2.4 Glycogenesis
Glycogen is the major form of carbohydrate storage in animals or the starch equivalent in
plants. When glucose concentration in the blood is elevated, primarily after meal, glycogen-
esis is initiated in the liver and muscle cells. While the storage of glucose in the liver is to main-
tain the level between meal, and hence for utilization by the body in general, glucose storage
in the muscle is for utilization by the muscle itself.
Chemically, glycogen is a highly branched polysaccharide or polymer of glucose. The cas-
cade of events involved in the formation of glycogen from α-D-glucose is shown in Fig. 2.5.
The process occurs within the cytosol and is energy dependent that is supplied by the
ATP and uridine triphosphate (UTP). The reaction starts by the hexokinase (HK) or glucoki-
nase (GK) enzyme-catalysed reaction that leads to the phosphorylation of glucose to form
G6P which is further acted by phosphoglucomutase (PGM) to form glucose-1-phosphate
(G1P). A further enzymatic action (glucose-1-phosphate uridylyltransferase) leads to the for-
mation of UDP-glucose (see Fig. 2.5). The key enzyme in glycogen synthesis which is under
regulation by various hormonal and metabolic mediators is glycogen synthase (GS).
The synthesis of glycogen from UDP-glucose requires further enzyme-catalysed steps:
The enzyme glycogen synthase generates a chain of glucose monomers with
α(1 ! 4) glycosidic linkages while amylo-α(1,4 ! 1.6)-glucosyltransferase (also called
FIG. 2.5 Glycogen synthesis. The conversion of glucose to glucose-1-phosphate (G1P) takes place via the G6P in-
termediate which is further acted by phosphoglucomutase (PGM). The enzyme glucose-1-phosphate uridylyl-
transferase, also known as UDP-glucose pyrophosphorylase, catalyses the formation of UDP-glucose from G1P
and UTP. By using UDP-glucose as a source of glucose, the glycogen chain is elongated by adding one glucose mol-
ecule at the reducing end through the action of glycogen synthase (GS).
FIG. 2.7 Schematic presentation of glycogen. The polysaccharides of glucose through α(1 ! 4) linkage and
branching via α(1 ! 6) glycosidic bonds lead to highly branched layers of glycogen as an energy storage system.
The branching system in glycogen not only increases water solubility but also the terminal residues that are readily
acted upon by enzymes (glycogen phosphorylase, Section 2.5) to release glucose when required.
Key fact:
As a key enzyme for the synthesis of glycogen, the glycogen synthase is highly regulated by various
metabolic regulators. For example, it is activated by insulin released from pancreatic β-cells in re-
sponse to postprandial increase in blood glucose or the G6P substrate precursor; while glucagon and
sympathetic/adrenergic (epinephrine) stimuli inhibit it. It also serve as a therapeutic target for
many drugs and natural products. Other therapeutic targets for natural products are the hexoki-
nase/glucokinase enzymes which can be upregulated (expression or activity) to increase glycogen
synthesis. Increased glycogen synthesis means reduced level of blood glucose.
2.5 Glycogenolysis
FIG. 2.8 The process of glycogenolysis. The breakdown of glycogen through the concerted action of two group of
enzymes are shown. Note that the effect of glycogen phosphorylase that acts on α(1 ! 4) glycosidic bonds would be
terminated at the α(1!6) branches until debranching enzymes remove this restriction and expose the next series of
α(1 ! 4) glycosidic bonds.
Key facts:
Glycogen phosphorylase is activated by calcium ions, epinephrine and glucagon and inhibited by
insulin and glucose. It does also serve as an important drug target for the control of glucose release
from its storage.
After shortening of the glycogen chains by glycogen phosphorylase, branches are removed
by the action of two enzymes. The oligo α(1! 6) to α(1 ! 4) glucan-transferase removes the
outer three of the four glucose residues attached at a branch and transfer them to the non-
reducing end of another chain, while the exposed α(1 ! 6) branch point is acted by the
debranching enzyme, amylo-α-(1,6)-glucosidase. The removal of the branching further allows
the phosphorylase enzyme to shorten the glycogen branches (Fig. 2.8).
The released G1P through the glycolysis process is converted to G6P by the action of phos-
phoglucomutase in a reverse reaction of glycogenesis. Finally, removal of the phosphate
group from G6P by the action of glucose-6-phosphatase (G6Pase) in the liver and kidney
allows glucose to be free to diffuse to the blood stream. In muscles, the G6P goes through
glycolysis for energy generation.
Geometrical Solids.
Representations of geometrical solids, were, as we have already seen,
the only objects which for many years were employed in the reflecting
stereoscope. The figures thus used are so well known that it is
unnecessary to devote much space to their consideration. For ordinary
purposes they may be drawn by the hand, and composed of squares,
rectangles, and circles, representing quadrangular pyramids, truncated, or
terminating in a point, cones, pyramids with polygonal bases, or more
complex forms in which raised pyramids or cones rise out of quadrangular
or conical hollows. All these figures may be drawn by the hand, and will
produce solid forms sufficiently striking to illustrate the properties of the
stereoscope, though not accurate representations of any actual solid seen
by binocular vision.
If one of the binocular pictures is not equal to the other in its base or
summit, and if the lines of the one are made crooked, it is curious to
observe how the appearance of the resulting solid is still maintained and
varied.
The following method of drawing upon a plane the dissimilar
representations of solids, will give results in the stereoscope that are
perfectly correct:—
Fig. 43.
Let l, r, Fig. 43, be the left and right eye, and a the middle point
between them. Let mn be the plane on which an object or solid whose
height is cb is to be drawn. Through b draw lb, meeting mn in c; then if the
object is a solid, with its apex at b, cc will be the distance of its apex from
the centre c of its base, as seen by the left eye. When seen by the right
eye r, cc′ will be its distance, c′ lying on the left side of c. Hence if the
figure is a cone, the dissimilar pictures of it will be two circles, in one of
which its apex is placed at the distance cc from its centre, and in the other
at the distance cc′ on the other side of the centre. When these two plane
figures are placed in the stereoscope, they will, when combined, represent
a raised cone when the points c, c′ are nearer one another than the
centres of the circles representing the cone’s base, and a hollow cone
when the figures are interchanged.
If we call e the distance between the two eyes, and h the height of the
solid, we shall have
e
ab : h = : cc,
2
he 5h
and cc = or, ,
2ab 4ab
which will give us the results in the following table, e being 2½, and ac 8
inches:—
Height of object. ab = ac - h cc
bc = h Inches.
1 7 0.179
2 6 0.4166
3 5 0.75
4 4 1.25
5 3 2.083
6 2 3.75
7 1 8.75
8 0 Infinite.
If we now converge the optic axes to a point b, and wish to ascertain
the value of cc, which will give different depths, d, of the hollow solids
corresponding to different values of cb, we shall have
e
ab : - d : cc′,
2
de
and cc′ = ,
2ab
which, making ac = 8 inches, as before, will give the following results:—
Depth. ab = ac + d cc′
cb = d Inches.
1 9 0.139
2 10 0.25
3 11 0.34
4 12 0.4166
5 13 0.48
6 14 0.535
7 15 0.58
8 16 0.625
9 17 0.663
10 18 0.696
11 19 0.723
12 20 0.75
The values of h and d when cc, cc′ are known, will be found from the
formulæ
2ab · cc
h= , and
e
2ab · cc′
d= .
e
As cc is always equal to cc′ in each pair of figures or dissimilar pictures,
the depth of the hollow cone will always appear much greater than the
height of the raised one. When cc = cc′ = 0.75, h:d = 3:12. When cc = cc′
= 0.4166, h:d = 2:4, and when cc = cc′ = 0.139, h:d = 0.8:1.0.
When the solids of which we wish to have binocular pictures are
symmetrical, the one picture is the reflected image of the other, or its
reverse, so that when we have drawn the solid as seen by one eye, we
may obtain the other by copying its reflected image, or by simply taking a
copy of it as seen through the paper.
When the geometrical solids are not symmetrical, their dissimilar
pictures must be taken photographically from models, in the same manner
as the dissimilar pictures of other solids.
Fig. 44.
The Rev. Mr. Egerton and I have obtained photographs of a bust, in the
course of ten minutes, with a very faint sun, and through an aperture less
than the hundredth of an inch; and I have no doubt that when chemistry
has furnished us with a material more sensitive to light, a camera without
lenses, and with only a pin-hole, will be the favourite instrument of the
photographer. At present, no sitter could preserve his composure and
expression during the number of minutes which are required to complete
the picture.
But though we cannot use this theoretical camera, we may make some
approximation to it. If we make the hole h a quarter of an inch, the pictures
br, &c., will be faint and indistinct; but by placing a thin lens a quarter of an
inch in diameter in the hole h, the distinctness of the picture will be
restored, and, from the introduction of so much light, the photograph may
be completed in a sufficiently short time. The lens should be made of rock
crystal, which has a small dispersive power, and the ratio of curvature of its
surfaces should be as six to one, the flattest side being turned to the
picture. In this way there will be very little colour and spherical aberration,
and no error produced by any striæ or want of homogeneity in the glass.
As the hole h is nearly the same as the greatest opening of the pupil,
the picture which is formed by the enclosed lens will be almost identical
with the one we see in monocular vision, which is always the most perfect
representation of figures in relief.
Fig. 45.
With this approximately perfect camera, let us now compare the
expensive and magnificent instruments with which the photographer
practises his art. We shall suppose his camera to have its lens or lenses
with an aperture of only three inches, as shewn at lr in Fig. 45. If we
cover the whole lens, or reduce its aperture to a quarter of an inch, as
shewn at a, we shall have a correct picture of the sitter. Let us now take
other four pictures of the same person, by removing the aperture
successively to b, c, d, and e: It is obvious that these pictures will all differ
very perceptibly from each other. In the picture obtained through d, we
shall see parts on the left side of the head which are not seen in the
picture through c, and in the one through c, parts on the right side of the
head not seen through d. In short, the pictures obtained through c and d
are accurate dissimilar pictures, such as we have in binocular vision, (the
distance cd being 2½ inches,) and fitted for the stereoscope. In like
manner, the pictures through b and e will be different from the preceding,
and different from one another. In the one through b, we shall see parts
below the eyebrows, below the nose, below the upper lip, and below the
chin, which are not visible in the picture through e, nor in those through c
and d; while in the picture through e, we shall see parts above the brow,
and above the upper lip, &c., which are not seen in the pictures through b,
c, and d. In whatever part of the lens, lr, we place the aperture, we obtain
a picture different from that through any other part, and therefore it follows,
that with a lens whose aperture is three inches, the photographic picture is
a combination of about one hundred and thirty dissimilar pictures of the
sitter, the similar parts of which are not coincident; or to express it in the
language of perspective, the picture is a combination of about one hundred
and thirty pictures of the sitter, taken from one hundred and thirty different
points of sight! If such is the picture formed by a three-inch lens, what must
be the amount of the anamorphism, or distortion of form, which is
produced by photographic lenses of diameters from three to twelve inches,
actually used in photography?[46]
But it is not merely by the size of the lenses that hideous portraits are
produced. In cameras with two achromatic lenses, the rays which form the
picture pass through a large thickness of glass, which may not be
altogether homogeneous,—through eight surfaces which may not be truly
spherical, and which certainly scatter light in all directions,—and through
an optical combination in which straight lines in the object must be conic
sections in the picture!
Photography, therefore, cannot even approximate to perfection till the
artist works with a camera furnished with a single quarter of an inch lens of
rock crystal, having its radii of curvature as six to one, or what experience
may find better, with an achromatic lens of the same aperture. And we may
state with equal confidence, that the photographer who has the sagacity to
perceive the defects of his instruments, the honesty to avow it, and the skill
to remedy them by the applications of modern science, will take a place as
high in photographic portraiture as a Reynolds or a Lawrence in the sister
art.
Such being the nature of single portraits, we may form some notion of
the effect produced by combining dissimilar ones in the stereoscope, so as
to represent the original in relief. The single pictures themselves, including
binocular and multocular representations of the individual, must, when
combined, exhibit a very imperfect portrait in relief,—so imperfect, indeed,
that the artist is obliged to take his two pictures from points of sight
different from the correct points, in order to produce the least disagreeable
result. This will appear after we have explained the correct method of
taking binocular portraits for the stereoscope.
No person but a painter, or one who has the eye and the taste of a
painter, is qualified to be a photographer either in single or binocular
portraiture. The first step in taking a portrait or copying a statue, is to
ascertain in what aspect and at what distance from the eye it ought to be
taken.
In order to understand this subject, we shall first consider the vision,
with one eye, of objects of three dimensions, when of different magnitudes
and placed at different distances. When we thus view a building, or a full-
length or colossal statue, at a short distance, a picture of all its visible parts
is formed on the retina. If we view it at a greater distance, certain parts
cease to be seen, and other parts come into view; and this change in the
picture will go on, but will become less and less perceptible as we retire
from the original. If we now look at the building or statue from a distance
through a telescope, so as to present it to us with the same distinctness,
and of the same apparent magnitude as we saw it at our first position, the
two pictures will be essentially different; all the parts which ceased to be
visible as we retired will still be invisible, and all the parts which were not
seen at our first position, but became visible by retiring, will be seen in the
telescopic picture. Hence the parts seen by the near eye, and not by the
distant telescope, will be those towards the middle of the building or
statue, whose surfaces converge, as it were, towards the eye; while those
seen by the telescope, and not by the eye, will be the external parts of the
object, whose surfaces converge less, or approach to parallelism. It will
depend on the nature of the building or the statue which of these pictures
gives us the most favourable representation of it.
If we now suppose the building or statue to be reduced in the most
perfect manner,—to half its size, for example,—then it is obvious that
these two perfectly similar solids will afford a different picture, whether
viewed by the eye or by the telescope. In the reduced copy, the inner
surfaces visible in the original will disappear, and the outer surfaces
become visible; and, as formerly, it will depend on the nature of the
building or the statue whether the reduced or the original copy gives the
best picture.
If we repeat the preceding experiments with two eyes in place of one,
the building or statue will have a different appearance; surfaces and parts,
formerly invisible, will become visible, and the body will be better seen
because we see more of it; but then the parts thus brought into view being
seen, generally speaking, with one eye, will have less brightness than the
rest of the picture. But though we see more of the body in binocular vision,
it is only parts of vertical surfaces perpendicular to the line joining the eyes
that are thus brought into view, the parts of similar horizontal surfaces
remaining invisible as with one eye. It would require a pair of eyes placed
vertically, that is, with the line joining them in a vertical direction, to enable
us to see the horizontal as well as the vertical surfaces; and it would
require a pair of eyes inclined at all possible angles, that is, a ring of eyes
2½ inches in diameter, to enable us to have a perfectly symmetrical view
of the statue.
These observations will enable us to answer the question, whether or
not a reduced copy of a statue, of precisely the same form in all its parts,
will give us, either by monocular or binocular vision, a better view of it as a
work of art. As it is the outer parts or surfaces of a large statue that are
invisible, its great outline and largest parts must be best seen in the
reduced copy; and consequently its relief, or third dimension in space,
must be much greater in the reduced copy. This will be better understood if
we suppose a sphere to be substituted for the statue. If the sphere
exceeds in diameter the distance between the pupils of the right and left
eye, or 2½ inches, we shall not see a complete hemisphere, unless from
an infinite distance. If the sphere is very much larger, we shall see only a
segment, whose relief, in place of being equal to the radius of the sphere,
is equal only to the versed sine of half the visible segment. Hence it is
obvious that a reduced copy of a statue is not only better seen from more
of its parts being visible, but is also seen in stronger relief.